| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Common Stock | 2.6M | $33.1M | $12.74 | 15 Jul 2022 | By Alpine ImmunoSciences, L.P. |
| ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Common Stock | 238K | $3.03M | $12.74 | 15 Jul 2022 | Direct |
| Serina Therapeutics, Inc. | Director | Series A Convertible Preferred Stock | 96.5K | $500K | $5.18 | 08 Apr 2025 | The Jay Venkatesan Legacy Trust |
| Elicio Therapeutics, Inc. | Director | Pre-Funded Warrants | 50K | $250K | $4.99 | 28 Jun 2024 | Direct |
| ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Common Stock | 18.6K | $237K | $12.74 | 15 Jul 2022 | By Raj Venkatesan as UTMA custodian for Nathaniel Graham Venkatesan |
| ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Common Stock | 18.6K | $237K | $12.74 | 15 Jul 2022 | By Raj Venkatesan as UTMA custodian for Reid Coleman Venkatesan |
| Elicio Therapeutics, Inc. | Director | Common Stock | 180K | $1.8K | $0.01 | 26 Nov 2024 | Direct |
| Elicio Therapeutics, Inc. | Director | Common Stock | 953 | $10.00 | $0.01 | 26 Nov 2024 | By Trust |
| ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Stock Option (Right to buy) | 70K | 15 Jul 2022 | Direct | ||
| Elicio Therapeutics, Inc. | Director | Common Warrants | 50K | 28 Jun 2024 | Direct | ||
| Serina Therapeutics, Inc. | Director | Stock Option (right to buy) | 10K | 07 Nov 2025 | Direct | ||
| Elicio Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 7.9K | 19 May 2025 | Direct | ||
| Elicio Therapeutics, Inc. | Director | Warrant to Purchase Common Stock | 0 | 26 Nov 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| SER | Serina Therapeutics, Inc. | 07 Nov 2025 | 1 | $0 | 4 | Director | 10 Nov 2025, 19:57 |
| ELTX | Elicio Therapeutics, Inc. | 19 May 2025 | 1 | $0 | 4 | Director | 20 May 2025, 16:07 |
| SER | Serina Therapeutics, Inc. | 08 Apr 2025 | 1 | $500K | 4 | Director | 10 Apr 2025, 16:03 |
| SER | Serina Therapeutics, Inc. | 12 Feb 2025 | 1 | $0 | 4 | Director | 13 Feb 2025, 17:03 |
| SER | Serina Therapeutics, Inc. | 12 Feb 2025 | 0 | $0 | 3 | Director | 13 Feb 2025, 17:02 |
| ELTX | Elicio Therapeutics, Inc. | 26 Nov 2024 | 2 | $500 | 4 | Director | 29 Nov 2024, 07:39 |
| ELTX | Elicio Therapeutics, Inc. | 21 Nov 2024 | 1 | $0 | 4 | Director | 25 Nov 2024, 07:35 |
| ELTX | Elicio Therapeutics, Inc. | 28 Jun 2024 | 2 | $250K | 4/A | Director | 02 Jan 2025, 16:05 |
| ELTX | Elicio Therapeutics, Inc. | 28 Dec 2023 | 1 | $0 | 4 | Director | 29 Dec 2023, 17:05 |
| ALPN | ALPINE IMMUNE SCIENCES, INC. | 15 Jul 2022 | 2 | $0 | 4 | Director, 10%+ Owner | 19 Jul 2022, 16:38 |
| ELTX | Angion Biomedica Corp. | 25 May 2022 | 1 | $14.1K | 4 | Officer, Director | 27 May 2022, 16:18 |
| ELTX | Angion Biomedica Corp. | 20 May 2022 | 2 | $101K | 4 | President and Chief Executive Officer and Director, Director | 25 May 2022, 17:58 |
| ELTX | Angion Biomedica Corp. | 03 Mar 2022 | 2 | $0 | 4 | President and Chief Executive Officer | 04 Mar 2022, 15:22 |
| ALPN | ALPINE IMMUNE SCIENCES, INC. | 03 Jan 2022 | 1 | $0 | 4 | Director, 10%+ Owner | 04 Jan 2022, 16:37 |
| ELTX | Angion Biomedica Corp. | 27 Dec 2021 | 2 | $730K | 4 | President and Chief Executive Officer and Director, Director | 29 Dec 2021, 15:08 |
| ELTX | Angion Biomedica Corp. | 20 Dec 2021 | 1 | $8.98K | 4 | President and Chief Executive Officer and Director, Director | 22 Dec 2021, 15:06 |
| ELTX | Angion Biomedica Corp. | 16 Dec 2021 | 2 | $106K | 4 | President and Chief Executive Officer and Director, Director | 20 Dec 2021, 17:44 |
| ALPN | ALPINE IMMUNE SCIENCES, INC. | 17 Sep 2021 | 1 | -$3.76M | 4 | Director, 10%+ Owner | 21 Sep 2021, 17:14 |
| ELTX | Angion Biomedica Corp. | 24 Jun 2021 | 2 | -$379K | 4 | President and Chief Executive Officer and Director, Director | 17 Dec 2021, 16:13 |
| ELTX | Angion Biomedica Corp. | 09 Feb 2021 | 4 | $4.59K | 4/A | President and Chief Executive Officer and Director, Director | 27 May 2022, 16:20 |